Cargando…

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

BACKGROUND. Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanoff, Hanna K., Chang, YunKyung, Lund, Jennifer L., O’Neil, Bert H., Dusetzina, Stacie B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016063/ https://www.ncbi.nlm.nih.gov/pubmed/27185615 http://dx.doi.org/10.1634/theoncologist.2015-0478

Ejemplares similares

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022)

DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma
por: Zheng, Jing, et al.
Publicado: (2023)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs
por: Díaz‐González, Álvaro, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
por: Sidali, Sabrina, et al.
Publicado: (2022)

Association of Tumor Cell Metabolic Subtype and Immune Response With the Clinical Course of Hepatocellular Carcinoma
por: Wei, Xiaolin, et al.
Publicado: (2023)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma
por: He, Guangming, et al.
Publicado: (2023)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review
por: Norero, Blanca, et al.
Publicado: (2023)

The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion
por: Liu, Jianwei, et al.
Publicado: (2023)

TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
por: Lima, Henrique A., et al.
Publicado: (2022)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center
por: Motz, Victoria L., et al.
Publicado: (2021)

Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings
por: Mai, Zhijun, et al.
Publicado: (2023)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma
por: Wang, Yuting, et al.
Publicado: (2023)

The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population‐based cohort study
por: Bengtsson, Bonnie, et al.
Publicado: (2022)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE
por: Bai, Shilei, et al.
Publicado: (2023)

Exploring the efficacy of (18)F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation
por: Yin, Yuping, et al.
Publicado: (2023)

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features
por: Liu, Jun, et al.
Publicado: (2021)

Improving detection performance of hepatocellular carcinoma and interobserver agreement for liver imaging reporting and data system on CT using deep learning reconstruction
por: Okimoto, Naomasa, et al.
Publicado: (2023)

Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions
por: Ray, Emily M, et al.
Publicado: (2017)

Signal transducer and activator of transcription 3‐mediated CD133 up‐regulation contributes to promotion of hepatocellular carcinoma
por: Won, Cheolhee, et al.
Publicado: (2015)

Fatty liver disease and pancreatic inflammation—A lethal combination?
por: Regnér, Sara, et al.
Publicado: (2023)

Dysregulated serum response factor triggers formation of hepatocellular carcinoma
por: Ohrnberger, Stefan, et al.
Publicado: (2015)

Added value of zoomed-echo-planar imaging diffusion-weighted imaging for evaluation of periampullary carcinomas
por: Liu, Jingjing, et al.
Publicado: (2023)

Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
por: Yeh, Yen-Po, et al.
Publicado: (2014)

Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics
por: Zeng, Wenjiao, et al.
Publicado: (2010)

The Impact of the COVID-19 Pandemic on Hepatocellular Carcinoma Time to Treatment Initiation: A National Cancer Database Study
por: Rasic, Gordana, et al.
Publicado: (2023)

Assessment of hepatic fibrosis and inflammation with look-locker T1 mapping and magnetic resonance elastography with histopathology as reference standard
por: von Ulmenstein, Sophie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0lq1t8m7uqlerrv8u0s1j9h18b